CD8A and COVID-19: When considering the translation of this platform into the clinic as a potential cell therapy for hospitalized COVID-19 patients, based on the level of enrichment and expansion demonstrated in this study, and a prediction of the number of SARS-COV-2 cells in the blood of COVID-19 individuals, we calculate an estimated capability to expand and deliver an average of approximately 3.5 × 109 SARS-CoV-2 CD8+ and/or CD4+ T cells back to the patient within 7-days (Fig. 6B).